

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

INSIDE INFORMATION AND POSITIVE PROFIT ALERT

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wishes to inform the shareholders of the Company and the potential investors that, based on the unaudited consolidated management accounts of the Company for the year ended 31 December 2014 prepared in accordance with Hong Kong Financial Reporting Standards, the Group’s unaudited annual results for the year ended 31 December 2014 is expected to record a substantial increase to a net profit of not less than HK\$620,000,000, while the net profit for the year ended 31 December 2013 is approximately HK\$48,000,000.

The substantial increase in annual net profit of the Group for the year ended 31 December 2014 is attributable to a number of factors as below:

- The overall gross profit of the Group was improved due to decrease in production costs through production capacity being steadily released and the production technology of enzymatic bulk amoxicillin being mature of the Inner Mongolian’s plant;
- In light of cessation of the operations of the Chengdu plant last year, a subsidy income from the local government of approximately HK\$390,000,000 was received during the year;
- The construction of the new facilities in Inner Mongolia plant gradually completed and commenced production this year. The amount of interest capitalised was decreased in the year. Thus, it resulted in increase in financial costs for the current year as compared with last year; and
- The fair value of the investment properties in Chengdu decreased as at 31 December 2014 compared with last year as the real estate market in China continued to be sluggish this year.

The information in this announcement is only based on the information currently available to the management. The results of the Group for the year ended 31 December 2014 have not yet been finalised nor reviewed by the audit committee and auditor of the Company. The final results of the Group for the year ended 31 December 2014 may be different to the information referred in this announcement.

Detailed annual results of the Group for the year ended 31 December 2014 will be published in the forthcoming 2014 annual results announcement and annual report 2014 of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 23 March 2015

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.